Why the study?
Does a cardiac troponin T immunoassay provide better diagnostic sensitivity and specificity for acute myocardial infarction compared to a CK-MB mass assay?
Does a cardiac troponin T immunoassay provide better diagnostic sensitivity and specificity for acute myocardial infarction compared to a CK-MB mass assay?
Answers are grounded in this paper and cite their sources.
Early evaluation of the cTnT immunoassay showed it to be highly sensitive for myocardial injury but less specific than CK-MB for the diagnosis of acute myocardial infarction.
We evaluated the analytical and clinical performance of an immunoassay for cardiac troponin T (cTnT). Within-run and total imprecision ranged from 1.6 to 11.3%. The sensitivity and linear range was 0.015 and 13 micrograms/L, respectively. Frozen samples were stable for at least 8 weeks. No interferences were seen with lipids or bilirubin (total and conjugated). Hemoglobin caused a negative bias at concentrations > 4 g/L. Heparinized plasma showed a 6% negative bias compared with serum. The clinical utility of cTnT was compared with that of creatine kinase (CK)-MB (mass assay). The sensitivity of cTnT measurements from 63 patients with acute myocardial infarction (AMI) (cTnT cutoff 0.1 microgram/L) was 60% at 0-3 h, 59% at 3-6 h, 94% at 6-9 h, 90% at 9-12 h, 99% at 12-24 h, 92% at 24-48 h, 83% at 48-72 h, and 100% at 72-96 h. Corresponding results for CK-MB (cutoff 5.0 micrograms/L and 2.5% relative index) were 45%, 64%, 82%, 97%, 87%, 81%, 54%, and 59%. The specificity of the markers from 49 non-AMI patients was 46% and 79% for cTnT and CK-MB, respectively. We show that CK-MB is more specific for diagnosis of AMI, and propose that cTnT is more sensitive to myocardial injury.
No takes yet. Share an insight, caveat, or question.
Wu et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: